/
NCEL
$3.69+$0.05 (+1.37%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$19.6M
5M shares
52-week range
$1.83 – $7.64
32% from low
Exchange
NASDAQ
CS
Borrow rate
13.50%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-3.60
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $10.1K | $11.4K | $11.4K | $3.3K |
| Gross profit | $0 | $0 | $0 | $0 | −$10.1K | −$11.4K | −$11.4K | −$3.3K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $4.3M | $708 | $1.7M | $99.6K | $5.9M | $9.0M | $5.9M | $422.1K |
| Operating income | −$5.8M | −$3.4K | −$4.2M | −$2.3M | −$11.9M | −$15.5M | −$11.8M | −$4.4M |
| EBITDA | −$5.8M | $0 | −$430.4K | $69.6M | −$11.9M | −$15.5M | −$11.8M | −$3.6M |
| Net income | −$6.7M | −$5.1K | −$5.4M | −$2.9M | −$11.9M | −$16.5M | −$12.2M | −$2.0M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -5.70 | -329.90 | -4.90 | -5.90 | -8.10 | -8.40 | -3.20 | -26.30 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $133M | $452.00 | $452.00–$452.00 | 1 |
| 2027 | $179M | $688.00 | $688.00–$688.00 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$10.10
Price
$3.69
Implied upside
+174%
Peer comparison
NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
www.newcelx.com- Employees
- 4
- IPO / List date
- Jan 26, 2021
Held by traders on TradeandTell
No one on the platform currently holds NCEL.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in NCEL as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NCEL yet.
